Microbix Biosystems Inc.
MBX.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -12.08% | -7.44% | 1.28% | 52.31% | 39.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.08% | -7.44% | 1.28% | 52.31% | 39.03% |
| Cost of Revenue | -9.14% | -14.33% | 0.54% | 9.63% | 16.11% |
| Gross Profit | -14.29% | -1.64% | 1.88% | 103.92% | 63.19% |
| SG&A Expenses | -4.21% | -9.59% | -11.56% | 14.01% | 10.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.60% | -10.51% | -4.35% | 10.77% | 12.72% |
| Operating Income | -76.17% | 43.96% | 121.18% | 240.13% | 206.48% |
| Income Before Tax | -103.40% | -58.69% | -45.14% | 15,788.95% | 308.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -106.34% | -62.36% | -49.16% | 15,147.09% | 301.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -106.34% | -62.36% | -49.16% | 15,147.09% | 301.63% |
| EBIT | -76.17% | 43.96% | 121.18% | 240.13% | 206.48% |
| EBITDA | -42.14% | 33.58% | 75.17% | 403.61% | 430.40% |
| EPS Basic | -105.11% | -62.10% | -49.25% | 19,000.00% | 301.47% |
| Normalized Basic EPS | -98.39% | 72.73% | 228.57% | 216.98% | 175.61% |
| EPS Diluted | -106.93% | -62.50% | -49.49% | 2,462.50% | 287.67% |
| Normalized Diluted EPS | -98.39% | 72.73% | 228.57% | 216.98% | 175.61% |
| Average Basic Shares Outstanding | 0.73% | -0.08% | -0.71% | -0.47% | -0.70% |
| Average Diluted Shares Outstanding | 0.67% | 0.14% | -1.48% | -1.35% | -1.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |